Pre-op topical analgesics vary in post-PRK pain control

Article

The duration and pattern of action of pain-suppressing nonsteroidal anti-inflammatory drugs (NSAIDs) used prior to photorefractive keratotomy (PRK) varies with the NSAID used, according to South Korean researchers.

The duration and pattern of action of pain-suppressing nonsteroidal anti-inflammatory drugs (NSAIDs) used prior to photorefractive keratotomy (PRK) varies with the NSAID used, according to South Korean researchers.

As reported in the Journal of Cataract and Refractive Surgery, the researchers conducted a comparative case series of 94 patients. The patients were randomly assigned to one of two groups. One group received ketorolac 0.5% in 1 eye and ofloxacin 0.3% in the other eye, the other group received diclofenac 0.1% in 1 eye and ofloxacin 0.3% in the other eye.

Three drops of each of the ophthalmic drugs were applied to each eye 30 minutes prior to PRK. The patients used a visual analogue scale to score the pain in each of their eyes at 6, 18, 24, 36, 48, 72 and 96 hours postoperatively.

The researchers found that the pain peaked between 24 and 36 hours postoperatively. The initial degree of pain reduction was constant for the NSAIDs, then dropped in the ketorolac group after 24 hours and in the diclofenac group after 36 hours. The postoperative time-serial pattern of the pain score changed in the diclofenac group compared with the pattern in the ofloxacin-treated eye; this change was not seen in the patients who received ketorolac. Neither NSAID affected visual outcomes.

To read an abstract of the study, visit the journal's website here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.